Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Integral Diagnostics Ltd. ( (AU:IDX) ) has provided an announcement.
Integral Diagnostics Ltd. reported strong financial results for FY25, marked by a 33.7% increase in consolidated revenue to $628.0 million and a 38.3% rise in operating EBITDA to $126.5 million. The merger with Capitol Health has been successfully integrated, resulting in synergies of $7.0 million, exceeding initial expectations. The company’s balance sheet remains robust with reduced leverage, and it declared a fully franked final dividend of 4.0 cents per share. This strategic merger has enhanced IDX’s operational scale and network, providing a stronger platform for clinical outcomes and future growth.
The most recent analyst rating on (AU:IDX) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Ltd. is a company operating in the healthcare industry, primarily focusing on diagnostic imaging services. The company is known for its comprehensive range of diagnostic imaging services and has a significant market presence in Australia.
Average Trading Volume: 1,043,981
Technical Sentiment Signal: Buy
Current Market Cap: A$998.1M
See more insights into IDX stock on TipRanks’ Stock Analysis page.